COMORBIDITY IN PATIENTS WITH OBESITY III IN DYNAMICS OF WEIGHT LOSS AFTER INTRAGASTRIC BALLOON INSTALLATION AND LAPAROSCOPIC SLEEVE GASTRECTOMY

Abstract

The cost of medical care for obese people is much higher than for people with normal weight.

The aim of the study – to evaluate the comorbidity in patients with obesity III in dynamics of weight loss after laparoscopic sleeve gastrectomy (LSG) and intragastric balloon installation (IBI).

Materials and Methods. 20 patients, 19–55 years old (16 women and 4 men) were involved to research, who were in Republican Specialized Scientific-Practical Medical Center of Surgery in 2016–2018. All patients had obesity III for WOG, 2011. Comorbity was evaluated by Nedogoda recommendations (2016), metabolic status by Cardiometabolic Disease Staging (Guo, 2015) scale.

Results and Discussion. It was established, that obesity III (BMI (49.4±2.5) kg / m²) is associated with dyslipidemia / hypertriglyce­ridemia in 85 % of cases; diabetes mellitus-2 / glucose intolerance – in 50 %, arterial hypertension in – 45 %; non-alcoholic fatty liver disease (NAFLD) – in 35 % of cases. LSG and IBI allow to achieve weight loss by 21.1 % and 16.2 % vs initial weight; both were similar effective (p > 0.05). It caused decreasing of comorbidity: glucose intolerance is reduced by 2 times, arterial hypertension – by 3 times; dyslipidemia – by 1.9 times; NAFLD – by 1.8 times in 6 months after intervention. LSG and IBI allow to improve parameters by scale Cardiometabolic Disease Staging, having achieved zero cardiometabolic risk in 35 % of patients, and at other patients – transition to easier stage. Weight loss and reduction of comorbidity after LSG and IBI are combined with decrease of proinflammatory cytokines – IL-6, TNF-a and C-reactive protein.